JP6408487B2 - Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体 - Google Patents

Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体 Download PDF

Info

Publication number
JP6408487B2
JP6408487B2 JP2015549613A JP2015549613A JP6408487B2 JP 6408487 B2 JP6408487 B2 JP 6408487B2 JP 2015549613 A JP2015549613 A JP 2015549613A JP 2015549613 A JP2015549613 A JP 2015549613A JP 6408487 B2 JP6408487 B2 JP 6408487B2
Authority
JP
Japan
Prior art keywords
antibody
ivalizumab
hiv
glycan
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015549613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503059A5 (enExample
JP2016503059A (ja
Inventor
ルイジャン ソン
ルイジャン ソン
デイビッド ディー． ホー
デイビッド ディー． ホー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JP2016503059A publication Critical patent/JP2016503059A/ja
Publication of JP2016503059A5 publication Critical patent/JP2016503059A5/ja
Application granted granted Critical
Publication of JP6408487B2 publication Critical patent/JP6408487B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015549613A 2012-12-18 2013-12-18 Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体 Active JP6408487B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261738777P 2012-12-18 2012-12-18
US61/738,777 2012-12-18
US201361864942P 2013-08-12 2013-08-12
US61/864,942 2013-08-12
PCT/US2013/076051 WO2014100139A1 (en) 2012-12-18 2013-12-18 Glycan-modified anti-cd4 antibodies for hiv prevention and therapy

Publications (3)

Publication Number Publication Date
JP2016503059A JP2016503059A (ja) 2016-02-01
JP2016503059A5 JP2016503059A5 (enExample) 2016-03-10
JP6408487B2 true JP6408487B2 (ja) 2018-10-24

Family

ID=50979141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549613A Active JP6408487B2 (ja) 2012-12-18 2013-12-18 Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体

Country Status (7)

Country Link
US (1) US9790276B2 (enExample)
EP (1) EP2934589B1 (enExample)
JP (1) JP6408487B2 (enExample)
CN (1) CN105228650B (enExample)
ES (1) ES2862950T3 (enExample)
TW (1) TWI630215B (enExample)
WO (1) WO2014100139A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
AU2014360760B2 (en) 2013-12-02 2019-12-12 The Trustees Of Columbia University In The City Of New York Improved HIV-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
EP3261651B1 (en) * 2015-02-27 2022-05-04 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
JP6936221B2 (ja) * 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN114269778B (zh) * 2019-08-19 2024-10-01 洛克菲勒大学 具改良药物动力学的经酸碱度依赖性抗原结合活性工程化的抗人类免疫缺乏病毒抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU662891B2 (en) 1990-11-27 1995-09-21 Biogen Idec Ma Inc. Anti CD-4 antibodies blocking HIV-induced syncytia
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
CA2632828C (en) * 2005-12-12 2012-07-10 F. Hoffmann-La Roche Ag Antibodies against amyloid beta with glycosylation in the variable region
WO2008134046A1 (en) 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
US9156912B2 (en) * 2008-12-12 2015-10-13 The University Of Tokyo Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN103282385A (zh) * 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity

Also Published As

Publication number Publication date
US9790276B2 (en) 2017-10-17
US20160362493A9 (en) 2016-12-15
EP2934589B1 (en) 2021-01-13
CN105228650B (zh) 2018-11-16
WO2014100139A1 (en) 2014-06-26
CN105228650A (zh) 2016-01-06
EP2934589A1 (en) 2015-10-28
TWI630215B (zh) 2018-07-21
ES2862950T3 (es) 2021-10-08
US20150166662A1 (en) 2015-06-18
TW201441258A (zh) 2014-11-01
EP2934589A4 (en) 2016-08-10
JP2016503059A (ja) 2016-02-01

Similar Documents

Publication Publication Date Title
US9587022B2 (en) Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
US12338277B2 (en) Broadly neutralizing antibodies that target HIV ENV V3 N-glycans
US11414479B2 (en) Compounds specific to coronavirus S protein and uses thereof
US8637024B2 (en) Fusion antibodies for HIV therapy
EP2934589B1 (en) Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
CN110088131B (zh) 抗chikv抗体及其用途
US20230242624A1 (en) HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
US20240150484A1 (en) Non-activating antibody variants
CN119698429A (zh) Fcrn结合分子及使用方法
WO2017011413A1 (en) Bispecific molecules comprising an hiv-1 envelope targeting arm
US20250353925A1 (en) Coronavirus-inhibiting antibodies
US12012451B2 (en) Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics
WO2022006562A1 (en) Multispecific coronavirus antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180920

R150 Certificate of patent or registration of utility model

Ref document number: 6408487

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250